Novartis’s Fevipiprant Hit By Phase III Asthma Failure
ZEAL Studies Miss Efficacy In Moderate Disease
Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.
